Intrapleural Perfusion With Staphylococcal Enterotoxin C for Malignant Pleural Effusion: A Clustered Systematic Review and Meta-Analysis.
Jiang H, Yang XM, Wang CQ, Xu J, Huang J, Feng JH, Chen XF, Chen K, Zhan L, Xiao X, Xiao Z.
Front Med (Lausanne). 2022 Apr 25;9:816973. doi: 10.3389/fmed.2022.816973. eCollection 2022.
Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis.
Pan X, Hou Z, Zhang T, Ding Z, Ye F, Wang Z, Huang C, Wang P, Li X.
J Cardiothorac Surg. 2024 May 6;19(1):278. doi: 10.1186/s13019-024-02751-6.
Pleuritic Chest Pain: Sorting Through the Differential Diagnosis.
Reamy BV, Williams PM, Odom MR.
Am Fam Physician. 2017 Sep 1;96(5):306-312.
Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.
Matsuzaki Y, Shibata K, Yoshioka M, Inoue M, Sekiya R, Onitsuka T, Iwamoto I, Koga Y.
Ann Thorac Surg. 1995 Jan;59(1):127-31. doi: 10.1016/0003-4975(94)00614-D.
Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials.
Han X, Qin S, Liu S, Li Z.
World J Surg Oncol. 2025 Jul 14;23(1):278. doi: 10.1186/s12957-025-03887-y.
Addition of bevacizumab to thoracic perfusion for treating malignant pleural effusions.
Weng C, Yu D, Meng Z, Pan F.
Asian J Surg. 2024 May;47(5):2331-2332. doi: 10.1016/j.asjsur.2024.01.176. Epub 2024 Feb 8.
Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesothelioma.
Okubo K, Ishibashi H, Wakejima R, Baba S, Asakawa A, Seshima H.
JTCVS Open. 2023 Sep 14;16:977-986. doi: 10.1016/j.xjon.2023.09.005. eCollection 2023 Dec.
Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review.
Wang CQ, Liu FY, Wang W.
Medicine (Baltimore). 2022 Oct 7;101(40):e30749. doi: 10.1097/MD.0000000000030749.
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.
Aigner KR, Selak E, Gailhofer S.
Onco Targets Ther. 2017 Jun 19;10:3049-3057. doi: 10.2147/OTT.S134126. eCollection 2017.
Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer.
Fu T, Lin Y, Zeng Q, Yao W, Han L.
BMC Pulm Med. 2020 Jun 18;20(1):175. doi: 10.1186/s12890-020-01210-x.
